Introduction: The Paradox of Successful Reperfusion
The management of ST-elevation myocardial infarction (STEMI) has undergone a revolution over the last three decades. The implementation of primary percutaneous coronary intervention (PCI) and the development of potent antiplatelet therapies have dramatically reduced mortality rates from the levels seen in the pre-reperfusion era. However, despite these technical successes, in-hospital mortality for STEMI remains stubbornly high in absolute terms, particularly in high-risk subgroups. A growing body of evidence suggests that while restoring flow to the epicardial coronary artery is necessary, it is not always sufficient to prevent myocardial death. In fact, the act of reperfusion itself can trigger a secondary wave of damage known as reperfusion injury.
One of the most severe forms of reperfusion injury is intramyocardial hemorrhage (IMH). This occurs when the microvasculature, weakened by ischemia, ruptures upon the restoration of high-pressure blood flow, leading to the extravasation of erythrocytes into the myocardial interstitium. While IMH has long been recognized as a predictor of adverse long-term remodeling and heart failure, its immediate impact on acute, in-hospital survival has remained poorly defined. A landmark study recently published in NEJM Evidence by Vora et al. provides a critical link between hemorrhagic myocardial infarction (MI) and early mortality, offering a potential new diagnostic pathway using routine clinical biomarkers.
